A PHASE I SAFETY AND PHARMACOKINETIC STUDY OF EVEROLIMUS, AN ORAL MTOR INHIBITOR, IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION СтатьяPeveling-Oberhag J., Zeuzem S., Yong W.P., Kunz T., Paquet T., Bouillaud E., Urva S., Anak O., Sellami D., Kobalava Z.EUROPEAN JOURNAL OF CANCER. Том 47. 2011.
INFLAMMATION RESEARCH Сборник материалов конференции40th Annual Meeting of the European-Histamine-Research-Society. SPRINGER BASEL AG.